• Platelet b1 integrin2mediated signals control granule secretion and hemostasis • b1 integrin2mediated outside-in signaling is independent of direct kindlin-integrin interaction
Introduction
The rupture of atherosclerotic plaques leads to the exposure of matrix proteins, which in turn trigger arterial thrombosis, leading to stroke and cardiac infarction. Different platelet receptors sense the exposed matrix and induce platelet activation and secretion of prothrombotic molecules, leading to further platelet recruitment and finally thrombus formation. Integrins represent the major family of cell-adhesion receptors on platelets. They are heterodimeric transmembrane molecules consisting of a and b subunits. The aIIbb3 integrin is exclusively expressed on platelets and can bind von Willebrand factor (vWF), fibrinogen, and fibronectin. In addition to aIIbb3, platelets express three b1 integrins, a2b1, a5b1, and a6b1, albeit at lower levels, which bind to collagen, fibronectin, and laminin, respectively. Circulating platelets express integrins in a conformation with a low affinity for the ligand. At sites of vascular injury, extracellular stimuli, such as collagen binding to glycoprotein VI (GPVI), induce the formation of active integrins with high affinity for ligands. This process is termed integrin activation or integrin inside-out signaling and requires the direct interaction of talin and kindlins with the cytoplasmic domain of the b integrin subunit. 1, 2 Although the fundamental role of the aIIbb3 integrin for plateletmediated hemostasis is indisputable, the in vivo relevance of b1 integrins on platelets remains controversial because of either different approaches to target b1 integrin function in platelets, including the use of a2 or b1 integrin-deficient mice, 3, 4 b1 integrin2blocking
antibodies, synthetic collagen-derived peptides, or small-molecule inhibitors, [5] [6] [7] or to the different experimental methods used to model arterial thrombosis 8, 9 and to assay bleeding tendency. 3, 10 Depending on the assay, b1 integrins have been reported to be both crucial and dispensable for platelet accumulation in vivo. Several in vitro studies indicated an important role of a2b1 integrin in the activation of various signaling molecules that are known to induce integrin aIIbb3 activation, platelet spreading, and aggregation. 11, 12 In one study with two patients, investigators reported that the loss of a2b1 integrin is associated with minor bleeding 13, 14 attributable to defective a2b1 integrin function, resulting in impaired platelet adhesion and aggregation to collagen or collagen-derived peptides under shear conditions. 10, 15 Overall, the exact role of b1 integrins remains a matter of debate.
In the present study we therefore investigated the role of b1 integrins on platelets during arterial thrombosis by using mouse mutants that express different levels of b1 integrins or an activationdeficient b1 integrin. We report that b1-null mice or an activationdeficient b1 integrin mutant show prolonged bleeding times because of insufficient activation of Rac-1, actin dynamics, granule secretion, and platelet aggregation. Interestingly, platelets expressing 3% of wild-type b1 integrin show reduced adhesion to sites of vascular injury; however, bleeding times, Rac-1 activation, and degranulation are not affected. The relevance of these findings is discussed.
Materials and methods

Reagents and antibodies
Thrombin and heparin were purchased from Sigma-Aldrich and convulxin (CVX), adenosine 59-diphosphate, and U46619 were from Alexis. Hormcollagen was purchased from Nycomed. The following antibodies were used for flow cytometry: PE-integrin b1 (CD29), PE-IgG hamster isotype (Biolegend), PE-integrin b3 (CD61; eBioscience), FITC-integrin a2 (CD49b; Emfret), PE-integrin a5 (CD49e) and PE-integrin a6 (CD49f; PharMingen), FITC-9EG7 (active integrin b-1), IgG1 rat isotype control (BD Biosciences); FITC-GPIa, FITC-GPVI, FITC-GPIX, PE-CD62P, PE-JON/A (active Integrin aIIbb3; all from Emfret), FITC-IgG2a rat isotype control, FITC-IgG2b rat isotype control (NatuTec), and PEIgG2a rat isotype control (PharMingen).
The following antibodies were used for western blotting: antikindlin-3, 16 anti-Talin-1 (Sigma-Aldrich), antifibrinogen (g-chain) (Abcam), antithrombospondin-1, anti-VEGF, anti-vWF (Santa Cruz Biotechnologies, Inc), anti-GAPDH (Calbiochem), anti-Rac-1 (Cell Biolabs), anti-PAK1 (phosphorylated-Thr432)/PAK2 (phosphorylated-Thr402), anti-MLC (phosphorylated-Ser19), anti-MLC (Cell Signaling), anti-FAK (phosphorylated-Y397; Biosource), anti-FAK (Upstate), and anti-b1 integrin (Millipore).
Mice
Conditional integrin b1 mice (b1 fl/fl ), kindlin-3 2/2 , integrin b1 hypomorphic (b1 Hpm/fl ) mice, and Mx1-Cre transgenic mice have been described previously. 1, [17] [18] [19] Bone marrow chimeras were generated by injecting 6 3 10 6 bone marrow cells into the tail vein of lethally irradiated 8-week-old C57BL/6 mice. Three weeks later, Cre expression in the hematopoietic system was induced by two intraperitoneal injections of 250 mg of polyI/C (Amersham Biosciences) with a time lag of 2 days.
Platelet preparation
Heparinized whole blood was centrifuged to isolate platelet-rich plasma. Platelets were washed in Tyrodes buffer, pH 6.5 (134 mM NaCl, 2.9 mM KCl, 12 mM NaHCO 3 , 10 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid) containing 5 mM glucose and 0.35% bovine serum albumin (BSA) and were kept at 37°C. For experiments ex vivo, platelets were resuspended in Tyrodes buffer, pH 7.4, containing 5 mM glucose, 0.35% BSA, 1 mM CaCl 2 , and 1 mM MgCl 2 .
Flow cytometry
Heparinized blood was diluted 1:50 in Tyrodes buffer, pH 7.4, containing 5 mM glucose, 0.35% BSA, 1 mM CaCl 2 , and 1 mM MgCl 2 . To quantify surface receptor expression level, blood samples were incubated with fluorophore-conjugated antibodies for 15 minutes at room temperature and analyzed on a FACScalibur flow cytometer (Becton Dickinson, Heidelberg, Germany). For integrin activation assays, washed platelets were stimulated for 15 minutes with the indicated agonists and incubated with fluorophoreconjugated conformation sensitive antibodies.
Platelet spreading
Coverslips were coated with 1 mg/mL fibrinogen (Sigma-Aldrich) or 25 mg/mL acid soluble collagen I (Sigma-Aldrich) overnight, washed and blocked with 1% BSA. Washed platelets (1 3 10 6 ) were suspended in 150 mL of Tyrodes buffer (pH 7.4; 1 mM CaCl 2 , 1 mM MgCl 2 ), stimulated with 0.01U/mL thrombin, and seeded on coated coverslides in the presence or absence of 0.75 mM Mn 21 . After 45 minutes at 37°C, differential interference contrast microscopy was performed with a Zeiss Axiovert 200M microscope with a Plan-NEOFLUAR, 3100, 1.45 oil objective (Zeiss, Jena, Germany). Pictures were acquired via the use of Metamorph software (Molecular Devices). Platelet spreading area was analyzed using ImageJ software (http://rsbweb.nih.gov/ij/).
Carotid ligation model
Experiments were performed as described by Massberg et al. 20 In brief, carotid arteries of anesthetized mice were dissected and ligated by the use of a small suture for 5 minutes. To visualize platelet adhesion, fluorescently 29,79-dichlorofluorescein (Molecular Probes)-labeled platelets (200 3 10 6 /250 mL) from control and mutant mice were infused, and the number of adherent platelets at the lesion site was quantified by video-fluorescence microscopy with a high-speed, wide-field fluorescent microscope with a long distance condenser and a 203 (NA 0.95) water immersion objective and a coupled camera (ORCA-ER; Hamamatsu Photonics). Images were acquired and analyzed using a Cell^R software (Olympus). The number of adherent platelets per mm 2 is represented as percentage of adherent b1 1/1 platelets at the 5-minute time point.
Analysis of bleeding time
Ten-to twelve-week-old mice were anesthetized by constant isoflurane gasnarcosis and subcutaneous application of weight-adapted fentanyl (0.05 mg/kg; CuraMed Pharma GmbH) and placed on a 37°C heating pad. An 8-mm segment of the tail tip was cut off, and the bleeding tail was immediately placed into 37°C warm physiological saline solution. Time until bleeding vanished was measured. All experiments were stopped latest after 15 minutes by cauterization to prevent excessive blood loss.
Aggregation
To determine platelet aggregation, light transmission was measured over 10 minutes in a two-channel aggregometer (CHRONO-LOG) and was expressed as arbitrary units. Washed platelets (2 3 10 8 /mL) were stimulated with different agonists in Tyrodes buffer (pH 7.4, 1 mM CaCl 2 , 1 mM MgCl 2 ) in the presence or absence of fibrinogen (100 mg/mL) or Mn 21 (0.75 mM), respectively.
Evaluation of adenosine triphosphate (ATP) release
A luciferin-luciferase detection kit (CHRONO-LOG) was used to quantify the release of ATP platelets. For these experiments, platelets were stimulated in a lumino-aggregometer (CHRONO-LOG) under stirring conditions, in the presence of luciferase and luciferin. Emitted luminescence was recorded as arbitrary units, and values were expressed as signal ratio of collagen and CVX-stimulated platelets.
Serotonin and PF-4 release assays
Platelets were stimulated in an aggregometer (CHRONO-LOG) under stirring conditions for 8 minutes. Platelets were pelleted by centrifugation for 30 seconds. The serotonin and PF-4 contents within the supernatants were determined using the Serotonin ELISA (LDN, Germany) and PF-4 ELISA (Abcam) Kits following the manufacturer's instructions.
Granule protein release
Platelets were stimulated in an aggregometer in the absence of BSA as described previously. After 8 minutes, platelets were pelleted by centrifugation (20 000 3 g for 30 seconds) and immediately lysed in Laemmli buffer (60 mM Tris-Cl, pH 6.8; 2% sodium dodecyl sulfate; 10% glycerol; 5% b-mercaptoethanol; 0.01% bromophenol blue). Lysates were subjected to immunoblotting and probed with the indicated antibodies.
Rac-1 activity assay
Rac-1 activity was analyzed with a Rac-1 Activation-Assay-Kit (Cell Biolabs). Platelets were stimulated with 5 mg/mL fibrillar collagen for 60 seconds in an aggregometer as described and then lysed by addition of 23 lysis buffer (125 mM HEPES, pH 7.5; 750 mM NaCl; 5% NP-40; 50 mM MgCl 2 ; 5 mM EDTA; 10% glycerol) on ice. Cleared lysates were incubated with PAK-PBD agarose and processed according to the manufacturer's protocol. Rac-1-GTP binding was determined by western blot analysis.
Measurement of filamentous actin content
Platelets were stimulated with 5 mg/mL fibrillar collagen in an aggregometer under stirring conditions in the presence of 0.5 mM RGDS (Sigma-Aldrich). At indicated time points, platelets were fixed in 1.8% parformaldehyde, permeabilized in 0.02% Triton X-100 phosphatebuffered saline, and stained with FITC-phalloidin (Invitrogen). F-actin content was quantified using flow cytometry.
Statistical analysis
All data are shown as mean 6 SEM. To test significance level, an unpaired Student t test was performed, and a value of P , .05 was considered significant. If indicated, one-way analysis of variance followed by a Tukey multiple comparison test was performed.
Ethics statement
All animal experiments were performed with approval by the District Government of Bavaria (Munich, Germany).
Results
Genetic targeting of b1 integrin
To address the role of platelet b1 integrins for platelet activation, adhesion, and aggregation, we generated mouse strains with different b1 integrin expression levels and an activation-deficient b1 integrin mutant. We derived platelets from offspring (b1 fl/fl Mx1-Cre; b1 1/fl Mx1-Cre) of intercrosses between floxed b1 integrin mice and the inducible Mx1-Cre strain, 18 from b1 integrin hypomorphic mice, 17 and from Kindlin binding2deficient mice carrying the TT788/789AA substitutions in the b1 integrin cytoplasmic domain. 21 Because homozygous hypomorphic b1 integrin (b1 hpm/hpm ) mice expressing very low levels of functional b1 integrin and homozygous b1 TTAA/TTAA mice die at peri-implantation, we crossed b1
1/hpm and b1 1/TTAA mice, respectively, with floxed b1 integrin and Mx1-Cre mice to generate b1 hpm/fl Mx1-Cre and b1
Mx1-Cre mice. Injection of poly-IC induced the expression of the Crerecombinase, leading to the deletion of the floxed b1 integrin gene predominantly in hematopoietic cells resulting in blood cell-restricted b1-null (KO), heterozygous (HT), hypomorphic (Hpm), and b1 TTAA (TTAA) mice. To prevent off-target effects of the Mx1-Cre2mediated gene deletion described in other tissues, we restricted the deletion to the hematopoietic system by using bone marrow chimeras for in vivo experiments.
18
Differential b1 integrin expression in mutant mice
We first quantified the surface expression of platelet b1, a2, a5, and a6 integrins by using flow cytometry. Poly-IC treatment resulted in a loss of b1 integrin surface levels on platelets from b1 fl/fl Mx1-Cre mice, reduced the levels by approximately 51% in b1 1/fl Mx1-Cre mice, approximately 82% in b1 TTAA/fl Mx1-Cre, and approximately 97% in b1 hpm/fl Mx-Cre mice ( Figure 1A -B). The differences in b1 integrin expression levels were confirmed by western blot analysis ( Figure 1C) . A similar reduction in the surface expression of the b1 integrin2associated a2, a5, and a6 integrin subunits was measured in the different platelet populations (supplemental Table 1A ; see the For personal use only. on April 1, 2017. by guest www.bloodjournal.org From Blood Web site). Furthermore, we analyzed the distribution of b1 integrin expression on hypomorphic platelets, which showed a mean expression of 3% compared with wild-type platelets. Fluorescenceactivated cell sorting analysis revealed that 80% of the platelets from hypomorphic mice express ,8.5% of b1 integrins, whereas only 5% express more than 25% of b1 integrins compared with controls (supplemental Table 1B ). It has been previously shown that the reduced expression of b1 TTAA integrin was caused by increased degradation. 21 Expression of talin-1 (for quantification, see supplemental Figure 1 ) and kindlin-3 was similar in platelets of all genotypes ( Figure 1C) . Furthermore, surface levels of b3 integrin, GPVI, and GPIX also were unaffected by the different b1 levels ( Figure 1D ).
b1 integrin inside-out signaling depends on an intact kindlin-binding site
We then analyzed the b1 integrin activation state on platelets from the different mice. Active b1 integrins were quantified by flow cytometry by use of the conformation-specific 9EG7 antibody that recognizes the active conformation of b1 integrins and the measured values were then corrected for the different b1 integrin expression. Treatment with CVX, the thromboxane A analog U46619, and thrombin led to a similar b1 integrin activation on platelets from wild-type, heterozygous, and hypomorphic mice. In sharp contrast, all three agonists failed to activate the kindlin binding2deficient b1 TTAA integrin ( Figure 1E ). Importantly, the activation of aIIbb3 integrins was not affected by b1 integrin surface levels or the kindlin binding mutation ( Figure 1F ). These data show that an intact kindlin-3 binding site in b1 integrins is required for their activation in vivo and that an intact binding site for talin-1 alone is not sufficient to activate b1 integrins.
b1 integrin2mediated outside-in signaling and spreading is independent of kindlin-integrin interaction Next, we analyzed platelet adhesion and spreading on acidic soluble collagen. Acidic soluble collagen I is bound by a2b1 integrin via a repetitive GFOGER motif. This motif is not recognized by GPVI, which binds GPOn exposed on fibrillar collagen. 5, 22 In contrast to human platelets that can bind soluble collagen and generate intrinsic signaling without previous activation, mouse platelets require a weak intrinsic activation to spread on soluble collagen. 23 Taking this into account, we stimulated washed mouse platelets with 0.01 U/mL thrombin in the presence or absence of 0.75 mM Mn 21 . As depicted in Figure 2A , b1
Hpm and b1-null platelets showed a severe spreading defect on soluble collagen I both in the presence or absence of Mn 21 . Furthermore, they formed elongated filopodia and only occasionally small lamellipodia. Activation of b1
TTAA platelets also failed to form lamellipodia and showed a significantly reduced spreading (Figure 2A-B) . Notably, spreading of b1
Hpm platelets was not improved by increasing the coating concentration of collagen (supplemental Figure 2A) . Interestingly, however, bypassing integrin inside-out signaling by Mn 21 -treatment rescued the spreading defect in b1
TTAA platelets (Figure 2A-B) . In light of our previous observation showing that Mn 21 -induced platelet spreading is abolished in kindlin-32deficient platelets, 1 we conclude that a direct interaction between kindlin-3 and b1 integrin is not required for integrin outside-in signaling.
To further corroborate this finding we analyzed autophosphorylation of focal adhesion kinase (FAK) at position Tyr397 as an immediate effect of collagen-bound b1 integrin signaling. Indeed, b1
TTAA platelets showed robust FAK phosphorylation in the presence of Mn 21 , which was neither seen in b1-null nor Kindlin-32 null platelets ( Figure 2C ). Of note, platelet adhesion and spreading on the a6b1 ligand laminin was similarly affected (supplemental Figure 2B ). In contrast, adhesion and spreading on the aIIbb3 ligands fibrinogen (Figure 2A ) and fibronectin or on the GPVI substrate collagen-related peptide (supplemental Figure 2B) was not altered in any of the genotypes examined here. Because Mn 21 treatment of b1
TTAA platelets show normal spreading, these findings indicate that a direct interaction between the integrin cytoplasmic domain and kindlin-3 is required for inside-out signaling, but this interaction is dispensable for integrin-mediated, outside-in signaling and cytoskeletal reorganization during platelet spreading.
b1 integrins are important for platelet adhesion and hemostasis
We next investigated whether the in vitro defects have consequences in vivo. The reduced b1 integrin expression in b1 hpm mice and the expression of b1
TTAA integrins had no impact on thrombopoiesis because platelet counts were similar to control animals (data not shown). For studying platelet adhesion to vascular lesions in vivo, we used the in vivo carotid ligation model, in which platelets accumulate in a collagen-dependent manner 20 and which allows monitoring single-platelet adhesion to a defined subendothelial vessel wound by intravital microscopy over time. Consistent with an important role of collagen for platelet adhesion, we observed that b1 integrin2deficient platelets as well as hypomorphic and b1 TTAA mutant platelets, but not platelets from heterozygous b1 integrin knockout mice, showed a strong decrease in platelet adhesion to the wounded vessel wall 5 to 60 minutes after vascular injury ( Figure 3A ). These findings indicate that b1 integrins significantly contribute to primary adhesion to subendothelial lesions and that 50% but not the 3% of wild-type b1 integrins (present on b1 hypomorphic platelets) are sufficient to mediate this task. The reduced adhesion of b1 TTAA platelets is likely attributable to the activation defect of the b1 integrins, although we cannot fully rule out that the expression level of approximately 18% compared with wild-type platelets also contributes to the observed adhesion defect.
Next, we tested whether b1 integrins also play a role for occlusive thrombus formation and hemostasis using the tail-bleeding assay. Although wild-type, heterozygous, and animals carrying a floxed b1 integrin allele but no Mx1-Cre allele (b1 fl/fl , b1 TTAA/fl , b1 Hpm/fl ) showed similar bleeding times of 2 to 3 minutes, b1 integrin knockout and b1 TTAA mice showed significantly prolonged tail bleeding times of 8 to 9 minutes ( Figure 3B ), and kindlin-32 deficient mice exhibited the most severe bleeding defect as the result of impaired b1 and aIIbb3 integrin activation.
1 Surprisingly, hypomorphic mice showed normal bleeding times. Taken together, these data indicate that b1 integrins play a crucial role for stopping bleeding and as little as 3% of them are sufficient enabling a normal hemostasis.
Defective aggregation and granule secretion in b1
TTAA and b1-null mice
Occlusive thrombus formation requires a second wave of platelet recruitment, activation, and subsequent aggregation, which is triggered by the release of paracrine factors stored in platelet a and dense granules. To find an explanation for the normal tail bleeding times of b1 hypomorphic mice, we investigated platelet aggregation in more detail. In brief, washed platelets were activated with either 5 mg/mL fibrillar collagen or with 50 ng/mL CVX, which activates GPVI by inducing GPVI receptor dimerization and downstream signaling. 24 CVX induced aggregation of platelets of all genotypes ( Figure 4A ; supplemental Figure 3A) . In contrast, b1-deficient and b1
TTAA platelets failed to aggregate after stimulation with fibrillar collagen, whereas b1 hpm platelets showed an intermediate response ( Figure 4A ). Exogenous activation of b1 TTAA platelets by Mn 21 resulted in normal aggregation, but this did not occur in b1-deficient platelets ( Figure 4B ). This latter finding further supports the concept that the double threonine motif within the b1 integrin cytoplasmic domain is required for integrin inside-out but not for integrin outside-in signaling.
Unexpectedly, the addition of exogenous fibrinogen to washed platelets rescued the aggregation defect of b1
TTAA and b1-null platelets ( Figure 4B ). Platelets contain substantial amounts of For personal use only. on April 1, 2017. by guest www.bloodjournal.org From fibrinogen within their granules, which they release upon stimulation (eg, by collagen). Hence, the finding that exogenous fibrinogen is able to rescue defective aggregation of b1 TTAA and b1-null platelets suggests a novel role of b1 integrin in the regulation of fibrinogen release from a granules in platelets. We therefore tested whether b1 integrin-mediated signals are important for granule secretion in general. Dense granule secretion was quantified by measuring ATP release after addition of luciferin/luciferase reagent in an aggregometer. Platelets were stimulated either with 50 ng/mL CVX or 5 mg/mL fibrillar collagen, and values were calculated as a ratio between fibrillar collagen-and CVX-induced luminescence.
Although b1-null and b1 TTAA platelets showed a severe defect in dense granule secretion after fibrillar collagen stimulation, b1 hpm platelets showed an almost-normal exocytosis of dense granules upon collagen stimulation ( Figure 4C ; supplemental Figure 3B) . Furthermore, the defect in dense granule secretion of b1-null and b1 TTAA platelets was corroborated by reduced secretion of serotonin ( Figure 4D ). To analyze platelet a-granule secretion, we determined the cellular level of the a-granule cargo fibrinogen ( Figure 4E ; supplemental Figure 3C ) before and 8 minutes after agonist treatment (5 mg/mL fibrillar collagen or 50 ng/mL CVX) by immunoblotting. Our data show that stimulation with fibrillar collagen led to a decrease in cellular fibrinogen in wild-type and hypomorphic platelets but not in b1-null and b1 TTAA platelets. Importantly, the total fibrinogen content was similar in unstimulated platelets of all groups (supplemental Figure 3D) , and exocytosis of other a-granule cargo proteins such as thrombospondin, vWF or PF-4 were also b1 integrin-dependent, suggesting that b1 integrin2mediated signals control platelet granule release (Figure 4F-G; supplemental Figure 3E ). How does b1 integrin control platelet granule secretion? Platelet granule fusion with the outer platelet membrane requires the reorganization of the actin cytoskeleton. 25 ,26 Therefore, we analyzed F-actin dynamics after collagen stimulation by flow cytometry. Indeed b1-null platelets failed to increase their F-actin content after 60 seconds, whereas ;3% of b1 integrin were sufficient to rescue F-actin polymerization in hypomorphic platelets ( Figure 5A ).
The small GTPase Rac-1 is a central regulator of actin polymerization and granule secretion in platelets and is activated rapidly after platelet stimulation. 27 Previous studies showed that genetic and pharmacologic inhibition of Rac-1 efficiently blocks collagen-induced platelet granule secretion and reduces the stability of platelet aggregates under flow.
28 Moreover, it has also been shown that a2b1 integrins regulate actin dynamics and lamellipodia formation in platelets spread on soluble collagen in a Rac-12dependent manner. 29 Hence, we next examined the formation of active, GTP-bound Rac-1 within 60 seconds after collagen exposure. Hypomorphic and wildtype platelets showed robust Rac-1 activation within 60 seconds, which was not observed in b1 integrin2null platelets ( Figure 5B-C) . In line with the reduced Rac-1 activity, phosphorylation of the Rac-1 target proteins PAK1/2 was strongly reduced in b1-null platelets 90 and 240 seconds after collagen treatment. Importantly, also hypomorphic platelets showed significant PAK phosphorylation. In contrast, phosphorylation of MLC in b1 integrin-null platelets was not different ( Figure 5D ). These results show that 3% of b1 integrin expression is sufficient for rapid Rac-1 activation required to remodel the platelet actin cytoskeleton and granule secretion in response to fibrous collagen.
Discussion
Previous authors have investigated platelet-collagen interactions by using various knockout mouse mutants, pharmacologic inhibitors, and disease models in arterial thrombosis and hemostasis. Despite conflicting results, the current model suggests that both GPVI and integrin a2b1 play significant roles as adhesion receptors; however, whether a2b1 plays an additional crucial role in platelet intracellular signaling controlling platelet aggregation and thrombus formation has not been elaborated. To address the molecular role of b1 integrins for these processes, we generated mice expressing either very low levels of functional (wild-type) b1 integrin or an activationdeficient b1 integrin, which harbors a mutation in the binding site for the essential integrin activating protein kindlin. Our studies reveal critical and distinct roles for b1 integrins in thrombosis and hemostasis dependent on their expression levels: (1) high b1 integrin levels critically contribute to platelet adhesion at sites of vascular injury; (2) b1 integrins assemble signaling platforms required to initiate full-fledged platelet activation and platelet granule secretion in response to fibrillar collagen; and (3) the level of b1 integrins can decrease to as little as 3% for sufficient activation of Rac-1 and its downstream effector molecules to finally promote F-actin formation and initiate platelet granule secretion. Despite robust Rac-1 activation, hypomorphic platelets fail to spread on plates coated with high concentrations of soluble collagen I, suggesting that a certain number of b1 integrins (.3%) are required for platelet adhesion during spreading. Furthermore, the efficient release of dense granule cargo such as ATP or serotonin and a-granule cargo proteins such as fibrinogen is controlled by b1 integrin outside-in signaling and cannot be compensated by GPVI in the absence of b1 integrins. More potent, although rather nonphysiologic, stimuli such as CVX may mask the contribution of b1 integrin signaling and thereby underestimate its role during thrombotic processes. However, our experimental conditions might not account for complex in vivo situations, in which additional platelet-collagen interactions through vWF and b3 integrin as well as mechanical forces or soluble stimuli might contribute to platelet activation in the presence of plasma proteins such as fibrinogen.
In addition, our data on platelets expressing an activationdeficient b1 integrin are in line with the proposed model that a2b1 integrins directly participate in collagen signaling in an For personal use only. on April 1, 2017. by guest www.bloodjournal.org From activation-dependent manner. 10 Inside-out activation by a2b1 integrin is probably triggered by signals generated by GPVI. These signals can be overcome by external integrin activation by manganese, which rescues the defects in platelet adhesion, spreading, and aggregation of b1 TTAA platelets. Thus, upon GPVI-mediated a2b1 activation, collagen-bound a2b1 integrin generates GPVI independent outsidein signals that are sufficient to trigger the release of secondary agonists to fully activate platelets.
Our findings also revealed that b1 integrins on platelets require an intact kindlin binding motif for their activation. This important finding further corroborates previous studies by showing that a direct interaction between kindlin-3 and the b1 integrin cytoplasmic domain is required for platelet b1 integrin activation in vivo. 21 However, we also observed that the direct interaction of kindlin-3 with the b1 tail is not required for integrin outside-in signaling and for achieving platelet spreading, FAK phosphorylation, and platelet aggregation. A similar observation has been reported recently for b2 integrins, which form a trimeric complex together with kindlin-3 and Rack-1 in T cells, and that kindlin-3 binding to b2 integrin tails can even occur to a kindlin binding-deficient b2 integrin tail. 30 Thus, kindlins need to directly bind the integrin tails for inducing inside-out signaling but a direct contact is either not required or does not occur for triggering outside-in signals. In such a scenario the dissociation of kindlin-3 from the integrin tail after activation has occurred will enable binding of other cytoplasmic proteins to the integrin tail.
Because high levels of b1 integrins are required for primary platelet adhesion to exposed matrix at sites of vascular disease but very low levels are already sufficient to trigger platelet signals required for normal hemostasis, the use of novel therapeutic agents targeting b1 integrins might be a worthwhile approach to reduce arterial thrombosis without increasing the risk for bleeding. 
